« Return to News | CROs/Service Providers | Technology Solutions

PAREXEL advances early phase research technology

Tuesday, November 22, 2011 11:55 AM
PAREXEL International has enhanced its central nervous system (CNS)
capabilities for clinical development through the implementation of
functional magnetic resonance imaging (fMRI) technology in its Early Phase
units. This advanced imaging scanning measures hemodynamic response, or
change in blood flow, related to neural activity in the brain or spinal
cord. Through this approach, PAREXEL is able to provide sponsors with
improved testing paradigms for cognitive biomarkers and better understand
the impact of compounds earlier in disease progression.
 
PAREXEL is among the first to apply this technology broadly to multicenter trials with centralized imaging review processes to improve the quality, consistency and reproducibility of clinical data.
 
The research-enhanced fMRI technology provides greater speed, advanced image detail, and more scanning flexibility.  Enabled with 3 Tesla (3T) power--a unit of measurement quantifying the strength of the magnetic field--PAREXEL can conduct scans to evaluate regions of interest with more anatomical detail, and detect smaller drug induced changes in brain function. With this capability, image quality is increased significantly, and image acquisition times are shortened. This technology allows PAREXEL to not only assess regions of activity but also functional connectivity among neurological networks. Additionally, early phase CNS experts can determine which regions are activated or deactivated by certain drug effects. This more sensitive measurement capability supports complex clinical studies focused on disease course modification techniques and improved symptomatic therapies earlier in the progression of an illness. The approach can be a sensitive pharmacodynamic tool to demonstrate proof of mechanism, especially when used in conjunction with other corroborative CNS biomarkers.
Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.